Charles River Laboratories has grown revenue −1.5% a year over three years and 4.1% a year over five. Revenue growth, 3-year annual rate: −1.5% (Diagnostics & Research median +8.4%). Revenue growth, 5-year rate: +4.1%, growth has slowed since the five-year average. Years of annual history on file: 18, FY2008 to FY2025, as filed.

CRLCharles River Laboratories

Healthcare

$301.83+92% 1Y

$301.83

$145.5752 weeks$310.95

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue roughly flat (−1% year on year) and operating margin flat.

2 neutral, 1 without data

Revenue trend−1% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +4% a year.

Margin direction−0.9 points operating

Trailing-twelve-month operating margin, 2.2% now against 3.0% a year earlier.

All from SEC EDGAR, as of Jun 27, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearsbehind 84% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is CRL growing?

Charles River Laboratories has grown revenue −1.5% a year over three years and 4.1% a year over five.

−1.5%

Revenue growth, 3-year annual rate · Diagnostics & Research median +8.4% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +4.1%
Revenue growth, 5-year rate · −1.5% over three · growth has slowed since the five-year average
Years of annual history on file: 18
Years of annual history on file · FY2008 to FY2025, as filed

Details›